Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Appetite ; 174: 106012, 2022 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-35367482

RESUMO

Estrogens reduce 0.3 M NaCl intake and palatability in a widely used model of essential hypertension, the spontaneously hypertensive rats (SHRs). Here we investigated whether the inhibitory effects of ß-estradiol (E2, 10 µg/kg b.w. subcutaneously for 8 days) on water deprived partially-rehydrated (WD-PR) ovariectomized (OVX) adult female SHRs (fSHRs, n = 4-10/group) are related to interferences on brain angiotensin II AT1 receptors (AT1r). After WD-PR, E2 reduced 0.3 M NaCl intake (1.3 ± 0.6, vs. vehicle: 3.5 ± 1.2 ml/30 min), the number of hedonic responses to intraoral NaCl infusion (57 ± 11, vs. vehicle: 176 ± 32/min), and the relative angiotensin AT1r (Agtr1a) mRNA expression in the hypothalamus. Losartan (AT1r antagonist, 100 µg) intracerebroventricularly in OVX fSHRs treated with vehicle subcutaneously abolished 0.3 M NaCl intake (0.1 ± 0.1 ml/30 min) and only transiently reduced hedonic responses to intraoral NaCl. Losartan combined with E2 decreased the number of hedonic and increased the number of aversive responses to intraoral NaCl and abolished 0.3 M NaCl intake. E2 also reduced the pressor and dipsogenic responses to intracerebroventricular angiotensin II. The results suggest that AT1r activation increases palatability and induces NaCl intake in WD-PR fSHRs. E2 reduced hypothalamic Agtr1a mRNA expression, which may account for the effects of E2 on NaCl intake and palatability and intracerebroventricular angiotensin II-induced pressor and dipsogenic responses in OVX fSHRs. Future studies considering natural fluctuations in estrogen secretion might help to determine the degree of such interference in brain neuronal activity.


Assuntos
Angiotensina II , Losartan , Angiotensina II/farmacologia , Animais , Estradiol/farmacologia , Feminino , Humanos , Losartan/farmacologia , RNA Mensageiro , Ratos , Ratos Endogâmicos SHR , Receptor Tipo 1 de Angiotensina/genética , Cloreto de Sódio
2.
J Dent Res ; 101(2): 216-225, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-34328027

RESUMO

Periodontal disease (PD) is a polymicrobial chronic inflammatory condition of the supporting tissues around the teeth, leading to the destruction of surrounding connective tissue. During the progression of PD, osteoclasts play a crucial role in the resorption of alveolar bone that eventually leads to the loss of teeth if the PD is left untreated. Therefore, the development of antiresorptive therapies targeting bone-resorbing cells will significantly benefit the treatment of PD. Here, we demonstrate the inhibitory effect of CsinCPI-2, a novel cysteine peptidase inhibitor from the orange tree, on periodontitis-induced inflammation, alveolar bone loss, and osteoclast differentiation. Using the ligature-induced periodontitis model in mice, we show that treatment with CsinCPI-2 (0.8 µg/g of body weight) significantly reduced inflammatory cell infiltrate in the connective tissue and prevented the loss of alveolar bone mass (BV/TV) caused by PD, effects associated with diminished numbers of TRAP-positive multinucleated cells. Furthermore, CsinCPI-2 significantly downregulated the numbers of inflammatory cells expressing CD3, CD45, MAC387, and IL-1ß. In vitro, CsinCPI-2 inhibited RANKL-induced TRAP+ multinucleated osteoclast formation in mouse bone marrow macrophage cultures in a concentration-dependent manner. This effect was not due to cytotoxicity, as demonstrated by the MTT assay. CsinCPI-2 inhibited RANKL-induced mRNA expression of Acp5, Calcr, and Ctsk, as well as the RANKL-induced upregulation of Nfatc1, a crucial transcription factor for osteoclast differentiation. Based on our findings, CsinCPI-2 prevents bone loss induced by PD by controlling the inflammatory process and acting directly on osteoclastogenesis, suggesting an interesting potential for CsinCPI-2 in the strategy for PD treatment.


Assuntos
Perda do Osso Alveolar , Reabsorção Óssea , Cistatinas/farmacologia , Periodontite , Inibidores de Proteases/farmacologia , Perda do Osso Alveolar/tratamento farmacológico , Perda do Osso Alveolar/prevenção & controle , Animais , Diferenciação Celular , Camundongos , Osteoclastos , Osteogênese , Periodontite/tratamento farmacológico , Ligante RANK
3.
Br J Pharmacol ; 169(2): 400-12, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23351078

RESUMO

BACKGROUND AND PURPOSE: Bone resorption induced by interleukin-1ß (IL-1ß) and tumour necrosis factor (TNF-α) is synergistically potentiated by kinins, partially due to enhanced kinin receptor expression. Inflammation-induced bone resorption can be impaired by IL-4 and IL-13. The aim was to investigate if expression of B1 and B2 kinin receptors can be affected by IL-4 and IL-13. EXPERIMENTAL APPROACH: We examined effects in a human osteoblastic cell line (MG-63), primary human gingival fibroblasts and mouse bones by IL-4 and IL-13 on mRNA and protein expression of the B1 and B2 kinin receptors. We also examined the role of STAT6 by RNA interference and using Stat6(-/-) mice. KEY RESULTS: IL-4 and IL-13 decreased the mRNA expression of B1 and B2 kinin receptors induced by either IL-1ß or TNF-α in MG-63 cells, intact mouse calvarial bones or primary human gingival fibroblasts. The burst of intracellular calcium induced by either bradykinin (B2 agonist) or des-Arg(10) -Lys-bradykinin (B1 agonist) in gingival fibroblasts pretreated with IL-1ß was impaired by IL-4. Similarly, the increased binding of B1 and B2 ligands induced by IL-1ß was decreased by IL-4. In calvarial bones from Stat6-deficient mice, and in fibroblasts in which STAT6 was knocked down by siRNA, the effect of IL-4 was decreased. CONCLUSIONS AND IMPLICATIONS: These data show, for the first time, that IL-4 and IL-13 decrease kinin receptors in a STAT6-dependent mechanism, which can be one important mechanism by which these cytokines exert their anti-inflammatory effects and impair bone resorption.


Assuntos
Interleucina-13/metabolismo , Interleucina-4/metabolismo , Receptor B1 da Bradicinina/metabolismo , Receptor B2 da Bradicinina/metabolismo , Fator de Transcrição STAT6/genética , Animais , Linhagem Celular , Fibroblastos/metabolismo , Técnicas de Silenciamento de Genes , Gengiva/citologia , Humanos , Interleucina-1beta/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Knockout , Osteoblastos/metabolismo , RNA/metabolismo , RNA Interferente Pequeno/administração & dosagem , Receptor B1 da Bradicinina/genética , Receptor B2 da Bradicinina/genética , Fator de Necrose Tumoral alfa/metabolismo
4.
J Dent Res ; 89(8): 802-7, 2010 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20505053

RESUMO

The osteotropic interleukin-6 (IL-6) types of cytokines IL-6, IL-11, and leukemia inhibitory factor (LIF), but not oncostatin M, are expressed by human gingival fibroblasts, and their expressions are regulated by IL-1 and tumor necrosis factor-alpha (TNF-alpha). In the present study, we investigated whether signaling through Toll-like receptor 2 (TLR2) can affect the expression of these cytokines in human gingival fibroblasts. Lipopolysac-charide (LPS) from P. gingivalis was found to stimulate IL-6 and LIF mRNA and protein, but not IL-11 or OSM mRNA. Using two synthetic ligands acting specifically at TLR2 and siRNA knockdown of TLR2, we demonstrated the important role of TLR2 in the stimulation of IL-6 and LIF in gingival fibroblasts. Analysis of these data suggests that signaling through the innate immune system controls the expression of osteotropic cytokines in human gingival fibroblasts.


Assuntos
Reabsorção Óssea/fisiopatologia , Gengiva/metabolismo , Interleucina-6/biossíntese , Fator Inibidor de Leucemia/biossíntese , Receptor 2 Toll-Like/fisiologia , Análise de Variância , Células Cultivadas , Fibroblastos/metabolismo , Técnicas de Silenciamento de Genes , Gengiva/citologia , Humanos , Interleucina-11/biossíntese , Lipopolissacarídeos/farmacologia , Porphyromonas gingivalis/química , RNA Mensageiro/biossíntese , RNA Interferente Pequeno/metabolismo , Estatísticas não Paramétricas , Receptor 2 Toll-Like/agonistas , Receptor 4 Toll-Like/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA